



MERGER ANNOUNCEMENT

Competition and Consumer Protection Commission to carry out full investigation of the proposed acquisition by Baxter Healthcare Limited of certain assets of Fannin Limited

3 September 2015

The Competition and Consumer Protection Commission has determined to carry out a full (Phase 2) investigation in relation to the proposed transaction whereby Baxter Healthcare Limited would acquire sole control of certain assets pertaining to the medical aseptic compounding business of Fannin Limited.

Following a preliminary investigation, the Competition and Consumer Protection Commission has determined that a full investigation is required in order to examine if the acquisition will substantially lessen competition in markets for goods or services in the State. The companies have been informed of the decision that the Competition and Consumer Protection Commission intends to carry out a full investigation in relation to the proposed transaction. The Commission will publish the reasons for its determination to proceed to Phase 2 on its website no later than 60 working days after the date of the Determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

Interested parties are invited to make submissions no later than **5pm on Monday 14 September 2015**. Parties making submissions should indicate clearly what, if any, of the material submitted contains business secrets. Submissions should be marked "**M/15/026 – Baxter Healthcare/Fannin Compounding**" and should be addressed to Barry O'Donnell, Mergers Division, Competition and Consumer Protection Commission, PO Box 12585, Dublin 1 or sent by e-mail to barryodonnell@ccpc.ie.

Additional Information

Baxter Healthcare Limited is incorporated in the United Kingdom and is ultimately controlled by Baxter International Inc. Baxter Healthcare Limited manufactures and supplies healthcare products and devices used to treat patients with haemophilia, immune deficiencies, infectious diseases, cancer, kidney disease, trauma and other chronic medical conditions. In the State, Baxter Healthcare Limited supplies medical products and compounded medicines to customers, mainly hospitals.

Fannin Limited, incorporated in the State, is a provider of medical devices, medicines, diagnostic products and related services to the healthcare sector in the State. Fannin Limited is a subsidiary of DCC Vital Limited which is controlled by DCC plc, an international sales, marketing, distribution and business support services group. The Target Assets comprise the assets of Fannin Limited which are used exclusively in the manufacture and supply of aseptically prepared compounded medicines to customers, mainly hospitals, in the State.